Glycogen synthase kinase 3β sustains invasion of glioblastoma via the focal adhesion kinase, Rac1, and c-Jun N-terminal kinase-mediated pathway

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 564-574

  Chikano, Yuri ^a   Domoto, Takahiro ^a   Furuta, Takuya ^a   Sabit, Hemragul ^a   Kitano Tamura, Ayako ^a   Pyko, Ilya V ^a   Takino, Takahisa ^a   Sai, Yoshimichi ^a   Hayashi, Yutaka ^a   Sato, Hiroshi ^a   Miyamoto, Ken Ichi ^a   Nakada, Mitsutoshi ^a   Minamoto, Toshinari ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAC1 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MATRIX METALLOPROTEINASE 14; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL MOTILITY; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOCHEMISTRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHASE CONTRAST MICROSCOPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CELL MOTION; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR MATRIX; METABOLISM; PATHOLOGY; PSEUDOPODIUM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GLIOBLASTOMA; GLYCOGEN SYNTHASE KINASE 3; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MICE; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PSEUDOPODIA; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION;

EID: 84923327165     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0479     Document Type: Article

References (50)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Jones TS, Holland EC. Standard of care therapy for malignant glioma and its effect on tumor and stromal cells. Oncogene 2012;31:1995-2006.
3. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010;16:2443-9.
4. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 2013;10:14-26.
5. Bonavia R, Inda M, Cavenee WK, Furnari FB. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 2011;71:4055-60.
6. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 2009;15:4589-99.
7. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, et al. Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A 2011;108:3749-54.
8. Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res 2011;17:6-11.
9. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3β: role in therapeutic landscape and development of modulators. Br J Pharmacol 2010;160:1-19.
10. Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, et al. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3β. Anti-Cancer Agents Med Chem 2009;9:1114-22.
11. Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, et al. Glycogen synthase kinase-3 inhibition induces glioma cell death through c-Myc, nuclear factor-κB, and glucose regulation. Cancer Res 2008;68:6643-51.
12. Miyashita K, Kawakami K, Mai W, Shakoori A, Fujisawa H, Nakada M, et al. Potential therapeutic effect of glycogen synthase kinase 3βinhibition against human glioblastoma. Clin Cancer Res 2009;15:887-97.
13. 6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Carcinogenesis 2013;34:2206-17.
14. Nowiki MO, Dmitrieva N, Stein AM, Cutter JL, Goldewski J, Saeki Y, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro-Oncology 2008;10:690-9.
15. Williams SP, Nowiki MO, Liu F, Press R, Goldewski J, Abdel-Rasoul M, et al. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res 2011;71:5374-80.
16. Zou Q, Hou Y, Shen F, Wang Y. Polarized regulation of glycogen synthase kinase-3β is important for glioma cell invasion. PLoS ONE 2013;8:e81814.
17. Sun T, Rodriguez M, Kin L. Glycogen synthase kinase 3 in the world of cell migration. Develop Growth Differ 2009;51:735-42.
18. Bhat R, Xue Y, Berg S, Hellberg S, Ormö M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003;278:45937-45.
19. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, et al. Deregulated glycogen synthase kinase 3β sustains gastrointestinal cancer cell survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res 2009;15:6810-9.
20. Kudo T, Takino T, Miyamori H, Thompson EW, Sato H. Substrate choice of membrane-type 1 matrixmetalloproteinases is dictated by tissue inhibitor of metalloproteinase-2 levels. Cancer Sci 2007;98:563-8.
21. Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL. Implications of Rho GTPase signaling in glioma cell invasion and tumor progression. Front Oncol 2013;3:241.
22. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010;10:9-22.
23. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 2011;12:413-26.
24. Tamase A, Muraguchi T, Naka K, Tanaka S, Kinoshita M, Hoshii T, et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009;106:17163-8.
25. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, et al. Inhibition of GSK3β attenuates proliferation of human colon cancer cells in rodents. Cancer Sci 2007;98:1388-93.
26. MEXT LifeScience Portalsite [Internet]. Tokyo, Japan: Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology in Japan [updated 2006 June 1; cited 2014 October 14]. Available from: http://www.lifescience.mext.go.jp/policies/pdf/an-material011.pdf.
27. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001;61:2744-50.
28. Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett 2008;582:2102-11.
29. Sahai E, Marshall CJ. Rho-GTPase and cancer. Nat Rev Cancer 2002;2:133-42.
30. Lazer G, Katzav S. Guanine nucleotide exchange factors for Rho GTPases: good therapeutic targets for cancer therapy? Cell Signal 2011;23:969-79.
31. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007;64:58-78.
32. Kobayashi T, Hino S, Oue N, Asahara T, Zollo M, Yasui W, et al. Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesion. Mol Cell Biol 2006;26:898-911.
33. Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 2014;14:598-610.
34. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, et al. Differential regulation of cell motility and invasion by FAK. J Cell Biol 2003;160:753-67.
35. Stylli SS, Kaye AH, Lock P. Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci 2008;15:725-37.
36. Liu C, Tu Y, Sun X, Jiang J, Jin X, Bo X, et al. Wnt/β-catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med 2011;11:105-12.
37. Zhang X, Chen T, Zhang J, Mao Q, Li S, Xiong W, et al. Notch1 promotes glioma cell migration and invasion by stimulating β-catenin and NF-κB signaling via AKT activation. Cancer Sci 2012;103:181-90.
38. Gong A, Huang S. FoxM1 and Wnt/β-catenin signaling in glioma stem cells. Cancer Res 2012;72:5658-62.
39. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
40. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6:931-40.
41. Golubovskaya VM, Huang G, Ho B, Yemma M, Morrison CD, Lee J, et al. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Mol Cancer Ther 2013;12:162-72.
42. Nomura N, Nomura M, Mizuki N, Hamada J. Rac1 mediates phorbol 12-myristate 13-acetate-induced migration of glioblastoma cells via paxillin. Oncol Rep 2008;20:705-11.
43. Alexander S, Friedl P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends Mol Med 2012;18:13-26.
44. Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 2012;4:127ra36.
45. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012;150:165-78.
46. Yoon CH, Hyun KH, Kim RK, Lee H, Lim EJ, Chung HY, et al. The small GTPase Rac1 is involved in themaintenance of stemness and malignancies in glioma stem-like cells. FEBS Lett 2011;585:2331-8.
47. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M, et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006;76:227-37.
48. Hwang SY, Jung JW, Jeong JS, Kim YJ, Oh ES, Kim TH, et al. Dominant-negative Rac increases both inherent and ionizing radiation-induced cell migration in C6 rat glioma cells. Int J Cancer 2006;118:2056-63.
49. UMIN-CTR Clinical Trial [Internet]. Tokyo, Japan: UMIN000005011. Chemotherapy for recurrent malignant glioma with combined usage of temozolomide and GSK3beta-inhibiting drugs [updated 2011 February 20; formal registration 2011 February 21; cited 2014 October 14]. Available from: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000002506&language=E.
50. Thotala DK, Hallahan DE, Yazlovitskaya EM. Inhibition of glycogen synthase kinase 3β attenuates neurocognitive dysfunction resulting from cranial irradiation. Cancer Res 2008;68:5859-68.